Any factor included as exclusion criteria in the participating centers treatment policy statement
REGISTRATION EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients receiving any other investigational agents
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Women who are pregnant or breastfeeding
Olaparib\r\n* No additional exclusion criteria
EXCLUSION CRITERIA FOR ENROLLMENT
EXCLUSION CRITERIA FOR T CELL TREATMENT:
PHASE I EXCLUSION CRITERIA
Pregnancy or breastfeeding, or intending to become pregnant during the study Exclusion Criteria based on Organ Function or Medical History Cardiovascular Patients who meet the following cardiovascular exclusion criterion will be excluded from study entry:
TREATMENT EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR REGISTRATION: Pregnant and/or breastfeeding
EXCLUSION CRITERIA FOR REGISTRATION: Prior treatment with neratinib
The following are considered criteria for exclusion from the exploratory genetic research:
Medication-related exclusion criteria
REGISTRATION/RANDOMIZATION EXCLUSION CRITERIA:
Preoperative Exclusion Criteria
Intraoperative Exclusion Criteria
EXCLUSION CRITERIA FOR STRATA A, B, D AND E
Subjects with CNS disease are eligible, with exceptions as noted in the exclusion criteria
TREATMENT EXCLUSION CRITERIA
TREATMENT EXCLUSION
Cohort specific exclusion criteria (cohorts and groups without applicable specific exclusion criteria are not listed separately and should follow the general exclusion criteria)
DONOR: The NMDP guidelines for exclusion criteria will be used.
SCREENING PHASE EXCLUSION CRITERIA
Ejection fraction < % will be an exclusion criteria for intensive chemotherapy; such patients may receive low intensity therapy
SCREENING EXCLUSION CRITERIA
Normal MRI exclusion criteria will apply; a standard MRI safety form will be used to identify potential conditions warranting exclusion
MEDICATION-RELATED EXCLUSION CRITERIA
ATEZOLIZUMAB-SPECIFIC EXCLUSION CRITERIA
BEVACIZUMAB-SPECIFIC EXCLUSION CRITERIA
RECIPIENT EXCLUSION CRITERIA
IMMUNOTHERAPY-RELATED EXCLUSION CRITERIA
MEDICATION-RELATED EXCLUSION CRITERIA:
REGISTRATION- EXCLUSION
ADDITION EXCLUSION CRITERIA FOR GROUP A (LOW TUMOR BURDEN) ONLY
STEP  SCREENING EXCLUSION CRITERIA
COHORT  EXCLUSION CRITERIA
COHORT  EXCLUSION CRITERIA
REGISTRATION EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR ALL STUDY ARMS
PART  EXCLUSION CRITERIA: Subjects < . M^
DRUG-SPECIFIC EXCLUSION CRITERIA
EXCLUSION CRITERIA (ENROLLMENT)
EXCLUSION CRITERIA (TRANSPLANT)
PANOBINOSTAT MAINTENANCE EXCLUSION
EXCLUSION CRITERIA FOR SCREENING:
EXCLUSION CRITERIA FOR LYMPHODEPLETION CHEMOTHERAPY, JCAR AND DURVALUMAB:
EXCLUSION CRITERIA FOR PATIENTS WITH CLL, MCL, OR ALL (COHORT A)
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Platelet count < ,/mm^
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Treatment with other investigational agent(s) within  days of planned lymphodepletion
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Serum creatinine > . mg/dL
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): SGOT >  x upper limit of normal
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Bilirubin > . mg/dL
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients who are HIV seropositive
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Women who are breastfeeding
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients who have contraindication to cyclophosphamide chemotherapy
EXCLUSION CRITERIA FOR TNBC: ANC < /mm^
EXCLUSION CRITERIA FOR TNBC: Platelet count < ,/mm^
EXCLUSION CRITERIA FOR TNBC: Treatment with other investigational agent(s) within  days of planned lymphodepletion
EXCLUSION CRITERIA FOR TNBC: SGOT >  x upper limit of normal
EXCLUSION CRITERIA FOR TNBC: Bilirubin > . mg/dL
EXCLUSION CRITERIA FOR TNBC: Patients who are HIV seropositive
EXCLUSION CRITERIA FOR TNBC: Breast-feeding women
EXCLUSION CRITERIA FOR TNBC: Patients who have contraindication to cyclophosphamide chemotherapy
ENTRECTINIB EXCLUSION CRITERIA: Incomplete recovery from any surgery prior to treatment
FIRST REGISTRATION-EXCLUSION:
DONOR EXCLUSION CRITERIA:
EXCLUSION CRITERIA - ARM A:
EXCLUSION CRITERIA - ARM B:
EXCLUSION CRITERIA FOR ENROLLMENT: The presence of active GVHD requiring treatment
SCREENING EXCLUSION CRITERIA
SCREENING EXCLUSION CRITERIA:
INTRA-OPERATION EXCLUSION CRITERIA (RANDOMIZATION ARMS ONLY)
Any patient ? and ? who presents for a colonoscopy and who does not have criteria for exclusion
BEVACIZUMAB-SPECIFIC EXCLUSION CRITERIA:
TREATMENT EXCLUSION CRITERIA:
CHEMOTHERAPY/CELL INFUSION EXCLUSION CRITERIA:
EXCLUSION CRITERIA FOR CONSENT B
Other exclusion criteria:
EXCLUSION CRITERIA AT TIME OF INFUSION:
INTRAOPERATIVE EXCLUSION CRITERIA:
Tumor type specific exclusion criteria
EXCLUSION CRITERIA FOR REGISTRATION: mucinous adenocarcinoma, borderline tumors
EXCLUSION CRITERIA FOR REGISTRATION: subjects who will undergo intraperitoneal chemotherapy
TREATMENT EXCLUSION CRITERIA:
EXCLUSION CRITERIA FOR CD+ TOPOFF WITHOUT CONDITIONING (COHORT ):
Laboratory criteria for exclusion within  days prior to randomization.
Platelet count < x^ / L Exclusion criteria for Group 
Pregnant or lactation. Exclusion criteria for HSV-Tk infusion:
PATIENT EXCLUSION CRITERIA:
DONOR EXCLUSION CRITERIA:
REGISTRATION  EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR TREATMENT: Hct less than or equal to %
EXCLUSION CRITERIA FOR TREATMENT: Hgb less than or equal to  g/dL
EXCLUSION CRITERIA FOR TREATMENT: ANC less than or equal to 
EXCLUSION CRITERIA FOR TREATMENT: Platelets less than or equal to ,
PHASE  AND GENERAL EXCLUSION CRITERIA
Patients should not enter the study if any of the following exclusion criteria are fulfilled
ADDITIONAL EXCLUSION CRITERIA FOR PATIENTS IN COMBINATION FULVESTRANT/CABOZANTINIB COHORT
SCREENING EXCLUSION CRITERIA:
EXCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT
EXCLUSION CRITERIA FOR MAINTENANCE THERAPY
Other Exclusion Criteria
EXCLUSION CRITERIA:
Must not meet any exclusion criteria defined in main study except for exclusion criteria \Subject must not have primary refractory disease\ which is related to prior carfilzomib
EXCLUSION CRITERIA SEARCH PHASE
Step I Exclusion Criteria:
Step II Exclusion Criteria:
TREATMENT EXCLUSION CRITERIA:
MEDICATION-RELATED EXCLUSION CRITERIA
METASTATIC SAFETY COHORT EXCLUSION CRITERIA
NEOADJUVANT EXCLUSION CRITERIA
EXCLUSION FOR ENROLLMENT/SCREENING (ARMS  AND )
EXCLUSION FOR TREATMENT (ARMS  AND )
Exclusion Criteria  Arms B and C
EXCLUSION CRITERIA PRIOR TO TRANSPLANT:
STAGE I EXCLUSION CRITERIA:
STAGE  EXCLUSION CRITERIA:
Exclusion of patients with creatinine > .
Exclusion of patients with bilirubin > .
There will be no exclusion criteria based on organ function
There will be no exclusion criteria based on organ function.
EXCLUSION CRITERIA - MAIN PROTOCOL
EXCLUSION CRITERIA FOR CONTINUING THERAPY ON THE EXTENSION PHASE:
Exclusion criteria will include all criteria listed for the main protocol
EXCLUSION CRITERIA PRIOR TO CELL COLLECTIONS FOR DENDRITIC CELL GENERATION:
EXCLUSION CRITERIA - RECIPIENT
IBRUTINIB-SPECIFIC EXCLUSION CRITERIA
IDELALISIB-SPECIFIC EXCLUSION CRITERIA
CARDIAC EXCLUSION CRITERIA:
There is no exclusion for the presence of cytopenias
REGISTRATION # EXCLUSION CRITERIA
Other Exclusion Criteria
IMMUNOTHERAPY-RELATED EXCLUSION CRITERIA:
RE-REGISTRATION EXCLUSION CRITERIA
REGISTRATION EXCLUSION CRITERIA
General Exclusion Criteria
Prisoner -Impending Fracture-Specific Exclusion Criteria
EXCLUSION CRITERIA FOR SCREENING:
EXCLUSION CRITERIA FOR TREATMENT:
EXCLUSION CRITERIA - INITIAL ENROLLMENT
EXCLUSION CRITERIA FOR TRANSPLANT RECIPIENT
EXCLUSION CRITERIA RELATED TO ZIV-AFLIBERCEPT
No prior treatment with systemic chemotherapy (except as noted in exclusion criteria # ).
Other Exclusion Criteria
COHORT  EXCLUSION CRITERIA FOR APHERESIS/TUMOR BIOPSY PORTION OF THE TRIAL (closed to enrollment as of //):
COHORT  EXCLUSION CRITERIA FOR IMMUNOTHERAPY PORTION OF THE TRIAL (closed to enrollment as of //):
COHORT  EXCLUSION CRITERIA:
REGISTRATION EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR PATIENTS
PATIENT EXCLUSION CRITERIA
EXCLUSION CRITERIA-PATIENTS
EXCLUSION CRITERIA-FCGs
EXCLUSION CRITERIA FOR PARENTS: Patient declines assent/consent (if >=  years)
EXCLUSION CRITERIA FOR PARENTS: Parent or child participated on prior PRISM intervention study
EXCLUSION CRITERIA FOR PATIENTS: Patient declines assent/consent (if >=  years)
EXCLUSION CRITERIA FOR PATIENTS: Patient participated on a prior PRISM intervention study
EXCLUSION - STUDY : Parkinson's disease
EXCLUSION - STUDY : The inclusion/exclusion criteria follows similar criteria for study # except only patients with confirmed peripheral neuropathy (VPT big toe greater than  volt) will be included; patients who have completed clinical study  would be eligible for study  if they develop CIPN as defined by VPT assessment
EXCLUSION CRITERIA FOR PATIENT PARTICIPANTS
PHASE : No provider exclusion criteria
PHASE A/B: PATIENT EXCLUSION CRITERIA: Non-English speaker
EXCLUSION CRITERIA SPECIFIC TO SURVIVORS:
EXCLUSION CRITERIA FOR BOTH SURVIVORS AND CO-SURVIVORS:
EXERCISE EXCLUSION CRITERIA:
There are no other agent-specific exclusion criteria
EXCLUSION CRITERIA FOR FOCUS GROUPS (PHASE I)
PATIENT EXCLUSION CRITERIA:
PREPROCEDURAL EXCLUSION CRITERIA:
PATIENTS EXCLUSION CRITERIA:
Hepatic encephalopathy Exclusion Criteria Specific to Arm B (Gastric Cancer) (Patients who meet any of the following specific exclusion criteria will be excluded from enrollment in Arm B:)
Ongoing treatment for epilepsy Exclusion Criteria Specific to Arm C (Metastatic Pancreatic Cancer) (Patients who meet any of the following specific exclusion criteria will be excluded from enrollment in Arm C:)
PATIENT PARTICIPANT EXCLUSION CRITERIA (PHASE  & )
EXCLUSION CRITERIA FOR GROUP A AND B
EXCLUSION CRITERIA-PATIENTS
Pre-procedure Exclusion Criteria
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have an uncontrolled infection are not eligible
READER STUDY EXCLUSION
REGISTRATION EXCLUSION
REGISTRATION EXCLUSION:
REGISTRATION EXCLUSION CRITERIA
REGISTRATION EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Pregnant or breastfeeding
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Karnofsky performance status < %
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Karnofsky performance status < %
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any uncontrolled active systemic infection
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Lactating or pregnant
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Uncontrolled cardiac arrhythmias
REGISTRATION/RANDOMIZATION EXCLUSION CRITERIA
Exclusion criteria for RPFNA
Exclusion criteria for study intervention
DRIVERS EXCLUSION CRITERIA
Exclusion Criteria for C-MBT studies:
Exclusion Criteria for P-MRS studies
Eligible for donation according to the transplantation center Exclusion Criteria Donor:
A history of miscarriage in the last  months, in and of itself, will not be considered an exclusion
Good performance status (as defined in Exclusion Criteria)
REGISTRATION EXCLUSION CRITERIA
EXCLUSION CRITERIA FOR CALYPSO TRANSPONDERS:
EXCLUSION CRITERIA (ALL PATIENTS)
Evidence of metastases (pelvic lymph node involvement is not an exclusion criteria); for patients with recurrent prostate cancer, oligometastatic disease ( or fewer visible metastases) is not an exclusion criterion
EXCLUSION CRITERIA FOR ORAL LESION AND NORMAL TISSUE
EXCLUSION CRITERIA FOR DRY MOUTH STUDY
EXCLUSION CRITERIA FOR GUM STUDY
No other appropriate agent-specific exclusion criteria
CANCER-SPECIFIC EXCLUSION CRITERIA
GENERAL MEDICAL EXCLUSION CRITERIA
STEP : EXCLUSION CRITERIA FOR TUMOR COLLECTION
Subject Exclusion Criteria for Optional Contrast MRIs Cohort  Only:
Common exclusion criterion
EXCLUSION CRITERIA - FOR MALE COHORT
SITE EXCLUSION CRITERIA:
PATIENT EXCLUSION CRITERIA:
PATIENT PARTICIPANTS EXCLUSION CRITERIA:
DRIVER EXCLUSION:
TRIAL EXCLUSION:
PATIENT EXCLUSION:
PROSPECTIVE STUDY POPULATION EXCLUSION
CHART AUDIT EXCLUSION CRITERIA:
There are no specific exclusion criteria for this study.
No exclusion criteria for this study
Other Exclusion Criteria
